Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
GENTAMICINE PANPHARMA 80 mg, solution injectable, Gentamicin Placebo, Metronidazole Biogaran 500 mg Placebo, Natriumchlorid-Lösung 0,9 % Deltamedica, Injektionslösung, METRONIDAZOLE BIOGARAN 500 mg, comprimé pelliculé
Pari Pharma GmbH
Acute mesenteric ischemia
1 trial -
GLASDEGIB , DAUNORUBICIN , AZACITIDINE , AMSACRINE , CYTARABINE , DECITABINE , FLUDARABINE , ETOPOSIDE , GILTERITINIB, IDARUBICIN , VENETOCLAX , MITOXANTRONE , IVOSIDENIB , CYTARABINE , CLADRIBINE , GEMTUZUMAB OZOGAMICIN
Istituto Gentili S.r.l.
Acute myeloid leukemia
1 trial -
GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets
Alfasigma S.p.A.
Juvenile idiopathic arthritis
1 trial -
GLPG0634, Jyseleca 200 mg film-coated tablets, Jyseleca 100 mg film-coated tablets
Alfasigma S.p.A.
Ulcerative colitis
1 trial -
GLUCOPHAGE 500 mg tabletki powlekane, Placebo
Bial Portela & Companhia S.A.
papillary thyroid carcinoma
1 trial -
GS-1720, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-4182
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-4182, Biktarvy 50 mg/200 mg/25 mg film-coated tablets, GS-1720
Gilead Sciences Pty Limited
HIV-1 Infection
1 trial -
GS-5245 tablets 175 mg, GS-5245 tablets 350 mg
Gilead Sciences Pty Limited
COVID-19
1 trial -
GSK3196165 (Otilimab)
GlaxoSmithKline
Arthritis, Rheumatoid
1 trial -
Gabapentin
BRIGHT MINDS BIOSCIENCES INC.
Drug Dependence
1 trial -
Gabapentin 300mg
BRIGHT MINDS BIOSCIENCES INC.
Alcohol Drinking
1 trial -
Gabitril
Teva Pharma GmbH
Anxiety Disorders
1 trial -
Gabitril
Teva Pharma GmbH
Generalized Anxiety Disorder
2 trials -
Gabitril
Teva Pharma GmbH
Anxiety Disorder
1 trial -
Galcanezumab, Placebo to match LY2951742
Eli Lilly Co.
Chronic Migraine
1 trial -
Galcanezumab, Placebo to match LY2951742
Eli Lilly Co.
Migraine
1 trial -
Gantenerumab
Hoffmann-La Roche
Alzheimer Disease
1 trial -
Garetosmab
Regeneron UK Limited
Fibrodysplasia Ossificans Progressiva
1 trial -
Gazyvaro 1,000 mg concentrate for solution for infusion., Calquence 100 mg hard capsules, Calquence 100 mg film-coated tablets, Chlorambucil 2 mg tablets
Lacuna Pharma Pty Ltd
Chronic Lymphocytic Leukemia
1 trial -
Gazyvaro 1,000 mg concentrate for solution for infusion., Chlorambucil 2 mg tablets, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion., Venclexta, Venclyxto, Venclexta, Venclyxto, Venclexta, Venclyxto
Hoffmann-La Roche
Chronic Lymphocytic Leukemia (CLL)
1 trial -
Gazyvaro 1,000 mg concentrate for solution for infusion., Venclyxto 10 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Calquence 100 mg film-coated tablets, Venclyxto 100 mg film-coated tablets, Venclyxto 50 mg film-coated tablets, Calquence 100 mg hard capsules, Venclyxto 10 mg film-coated tablets, Calquence 100 mg hard capsules
AstraZeneca AB
Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
1 trial -
Gefurulimab
Alexion Europe SAS
Generalized Myasthenia Gravis with autoantibodies against acetylcholine receptor (AChR)
1 trial -
Gemcitabine
AstraZeneca
Biliary Tract Cancer
1 trial -
Gemcitabine 38 mg/mL concentrate for solution for infusion, Trodelvy 200 mg powder for concentrate for solution for infusion, KEYTRUDA 25 mg/mL concentrate for solution for infusion, Carboplatin 10 mg/ml concentrate for solution for infusion, Paclitaxel 6 mg/ml concentrate for solution for infusion, Abraxane 5 mg/ml powder for dispersion for infusion.
Gilead Sciences Pty Limited
PD-L1 Positive Metastatic Triple-Negative Breast Cancer
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources